Showing results (51-60 of 1,083) with videos related to
Sort By:
Pageof 109
Expert Review of Cardiovascular Therapy|July 15, 2020
An updated drug profile of ticagrelor with considerations on the treatment of patients with coronary artery disease and diabetes mellitusDario Calderone, Davide Capodanno, Dominick J AngiolilloExpert Opinion on Pharmacotherapy|July 24, 2024
The pharmacology of antiplatelet agents for primary, secondary, and tertiary prevention of ischemic strokeClaudio Laudani, Davide Capodanno, Dominick J AngiolilloExpert Opinion on Drug Metabolism & Toxicology|October 18, 2023
Evaluating the pharmacokinetic and pharmacodynamic impact of different modes of ticagrelor administrationMarco Spagnolo, Dominick J Angiolillo, Davide CapodannoExpert Review of Cardiovascular Therapy|February 9, 2010
Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonistDavide Capodanno, Kodlipet Dharmashankar, Dominick J AngiolilloNature Reviews. Cardiology|August 19, 2015
Switching P2Y12-receptor inhibitors in patients with coronary artery diseaseFabiana Rollini, Francesco Franchi, Dominick J AngiolilloThrombosis and Haemostasis|June 9, 2017
Antithrombotic therapy for acute coronary syndrome: Past, present and futureDirk Sibbing, Dominick J Angiolillo, Kurt HuberGiornale Italiano Di Cardiologia (2006)|May 13, 2011
[Antiplatelet and anticoagulant therapy in elderly patients]Davide Capodanno, Dominick J Angiolillo, Corrado TamburinoEuropean Heart Journal|December 2, 2009
Platelet thrombin receptor antagonism and atherothrombosisDominick J Angiolillo, Davide Capodanno, Shinya GotoNature Reviews. Cardiology|February 24, 2017
Antithrombotic therapy for patients with STEMI undergoing primary PCIFrancesco Franchi, Fabiana Rollini, Dominick J AngiolilloJournal of the American College of Cardiology|March 16, 2005
Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studiesRaúl Moreno, Cristina Fernández, Rosana Hernández, et al.Pageof 109